• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies
 

First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies

Options
  • Details
  • Files
BORIS DOI
10.7892/boris.13942
Publisher DOI
10.1002/14651858.CD004626.pub3
PubMed ID
23076906
Description
Several clinical studies have compared single with tandem (also called double) autologous stem cell transplantation (ASCT) as first-line treatment in patients with symptomatic multiple myeloma (MM), one of the leading indications for ASCT worldwide.
Date of Publication
2012
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Language(s)
en
Contributor(s)
Naumann-Winter, Frauke
Greb, Alexander
Borchmann, Peter
Bohlius, Julia Friederike
Institut für Sozial- und Präventivmedizin (ISPM)
Engert, Andreas
Schnell, Roland
Additional Credits
Institut für Sozial- und Präventivmedizin (ISPM)
Series
Cochrane database of systematic reviews
Publisher
WileyInterscience
ISSN
1469-493X
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: dd892c [ 9.04. 8:30]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo